Keywords: Deuterium, Deuterium, Contrast mechanisms, Preclinical.
Motivation: Mutations in isocitrate dehydrogenase (IDHm) define a distinct molecular class of gliomas. IDHm converts the normal metabolite α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (D-2HG), which drives tumorigenesis.
Goal(s): The IDHm inhibitor vorasidenib was recently approved for treatment of IDHm glioma patients. However, non-invasive methods of imaging IDHm activity in vivo are lacking.
Approach: Here, we show that deuterium metabolic imaging using diethyl-[3,3’-2H]-α-ketoglutarate allows quantification of D-2HG production and visualization of tumor burden specifically in mice bearing IDHm but not IDH wild-type gliomas.
Results: Importantly, diethyl-[3,3’-2H]-α-ketoglutarate provides an early response to vorasidenib that precedes MRI-detectable volumetric alterations in mice bearing intracranial IDHm gliomas in vivo
Impact: Our studies provide proof-of-concept evidence that diethyl-[3,3’-2H]-α-ketoglutarate informs on tumor burden and treatment response in IDHm gliomas. Clinical translation of diethyl-[3,3’-2H]-a-ketoglutarate will provide clinicians with a tool to monitor disease progression in IDHm glioma patients, which is currently challenging.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords